Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NDA Review Pilot Will Be Mandatory, Assuming Program Flies At All

Executive Summary

The proposed review model for new molecular entity new drug applications and original biologics license applications remains under discussion along with several other Prescription Drug User Fee Act reauthorization issues.

You may also be interested in...



PDUFA V: Review Model Evaluators Will Observe All FDA-Sponsor Meetings

Interim and final assessments will help determine which parts of the new, longer application review help FDA take more first-cycle actions.

PDUFA V Agreement Appears Set Between FDA And Industry

Final package expected to be published in late summer following clearance by the administration.

PDUFA V Agreement Set In Four Areas, But Broad FDA/Industry Talks Continue

FDA and industry have reached agreement on four issues in the Prescription Drug User Fee Act reauthorization, including adjustments to risk-benefit policy and creation of a meta-analysis team.

Related Content

Topics

UsernamePublicRestriction

Register

PS053187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel